Pharmaceutical Executive Brings Extensive Product Development &
Operational Expertise to
“Adam’s expertise in growing and leading biotech companies and R&D organizations will be critical as we progress our lead investigational product, NeoCart®, through a Phase 3 pivotal trial and ultimately toward potential approval and commercialization,” said the Company’s Chairman,
“I am excited to join Histogenics as the Company builds out its operational functions, technology platform and commercial infrastructure. I believe that Histogenics has a significant opportunity with its lead investigational product NeoCart®, which has the potential to become an innovative therapy alternative to the current standard of care for cartilage repair in the knee,” said
Prior to joining Histogenics,
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at http://www.histogenics.com.
NeoCart®, our Phase 3 investigational product is an implant produced using a patient’s own cartilage cells. A Phase 1 clinical trial conducted in
For additional inquiries, please email us at InvestorRelations@histogenics.com or call us at 781.547.7900.
Forward Looking Statement
This press release contains “forward looking statements” including statements about Histogenics’ future operating results, product development, potential alliances and intellectual property. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
Most Popular Stories
- Pandora Tumbles in Late Trading
- Sporty Ford Fiesta Fires on All 3 Cylinders
- Stop-Start Engines Save Gas, Reduce Emissions
- World Tensions Don't Curb Enthusiasm for Stocks
- Russia Fears Lasting Damage From Ukraine Crisis
- Visa, Amazon Results Drag Down the Street
- U.K. Economy Surpasses Pre-Crisis Peak
- Ohio State Band Chief Fired After Probe
- Shia LaBeouf Plea Deal, Alcoholism Treatment
- Hispanic Leader Goes the Extra Mile